INAB
Price:
$0.304
Market Cap:
$14.22M
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incy...[Read more]
Industry
Biotechnology
IPO Date
2021-07-30
Stock Exchange
NASDAQ
Ticker
INAB
According to IN8bio, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.37. This represents a change of -72.00% compared to the average of -1.32 of the last 4 quarters.
The mean historical PE Ratio of IN8bio, Inc. over the last ten years is -16.46. The current -0.37 PE Ratio has changed 124.82% with respect to the historical average. Over the past ten years (40 quarters), INAB's PE Ratio was at its highest in in the June 2024 quarter at -1.06. The PE Ratio was at its lowest in in the March 2018 quarter at -29.66.
Average
-16.46
Median
-14.12
Minimum
-37.70
Maximum
-1.37
Discovering the peaks and valleys of IN8bio, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 27.09%
Maximum Annual PE Ratio = -1.37
Minimum Annual Increase = -75.12%
Minimum Annual PE Ratio = -37.70
Year | PE Ratio | Change |
---|---|---|
2023 | -1.37 | -22.25% |
2022 | -1.77 | -68.60% |
2021 | -5.63 | -75.12% |
2020 | -22.62 | -40.00% |
2019 | -37.70 | 27.09% |
The current PE Ratio of IN8bio, Inc. (INAB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.92
5-year avg
-13.82
10-year avg
-16.46
IN8bio, Inc.’s PE Ratio is greater than Reviva Pharmaceuticals Holdings, Inc. (-1.10), greater than Cue Biopharma, Inc. (-0.63), greater than Lantern Pharma Inc. (-2.07), greater than Gracell Biotechnologies Inc. (-12.26), greater than Anixa Biosciences, Inc. (-8.32), greater than INmune Bio, Inc. (-3.01), greater than PolyPid Ltd. (-0.70), greater than Zura Bio Limited (-9.00), greater than Annexon, Inc. (-6.50), greater than Icosavax, Inc. (-8.27), greater than Wave Life Sciences Ltd. (-9.04), greater than Gain Therapeutics, Inc. (-0.93), less than TFF Pharmaceuticals, Inc. (-0.34), greater than aTyr Pharma, Inc. (-2.33), less than Palisade Bio, Inc. (-0.31), less than ContraFect Corporation (-0.11), less than Allarity Therapeutics, Inc. (-0.19), less than CNS Pharmaceuticals, Inc. (-0.00), less than Windtree Therapeutics, Inc. (-0.14),
Company | PE Ratio | Market cap |
---|---|---|
-1.10 | $44.68M | |
-0.63 | $28.70M | |
-2.07 | $36.82M | |
-12.26 | $989.87M | |
-8.32 | $102.74M | |
-3.01 | $116.32M | |
-0.70 | $23.40M | |
-9.00 | $230.86M | |
-6.50 | $607.51M | |
-8.27 | $769.04M | |
-9.04 | $639.91M | |
-0.93 | $26.81M | |
-0.34 | $6.20M | |
-2.33 | $131.12M | |
-0.31 | $4.25M | |
-0.11 | $1.72M | |
-0.19 | $7.01M | |
-0.00 | $4.60M | |
-0.14 | $1.66M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like IN8bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like IN8bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is IN8bio, Inc.'s PE Ratio?
How is the PE Ratio calculated for IN8bio, Inc. (INAB)?
What is the highest PE Ratio for IN8bio, Inc. (INAB)?
What is the 3-year average PE Ratio for IN8bio, Inc. (INAB)?
What is the 5-year average PE Ratio for IN8bio, Inc. (INAB)?
How does the current PE Ratio for IN8bio, Inc. (INAB) compare to its historical average?